We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of CYP3A Genetic Polymorphisms on the Pharmacokinetics of Atorvastatin (ECGPPA)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00973986
First Posted: September 9, 2009
Last Update Posted: November 29, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Guangdong Province, Department of Science and Technology
Information provided by:
Liuhuaqiao Hospital
  Purpose
The aim of the study is to investigate the effects of CYP3A polymorphisms on the pharmacokinetics of Atorvastatin in Chinese subjects with coronary heart disease.

Condition Intervention Phase
Coronary Heart Disease Drug: Atorvastatin Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Study the Effect of CYP3A Genetic Polymorphisms on the Pharmacokinetics of Atorvastatin in Chinese Subjects With Coronary Heart Disease

Resource links provided by NLM:


Further study details as provided by Liuhuaqiao Hospital:

Primary Outcome Measures:
  • Compare the area under the plasma concentration versus time curve (AUC) and Area under the plasma concentration versus time curve (AUC) of atorvastatin with different CYP3A4*1G genotypes. [ Time Frame: 48h ]

Secondary Outcome Measures:
  • The pharmacokinetics of atorvastatin in Chinese with coronary heart disease. [ Time Frame: 48h ]

Enrollment: 20
Study Start Date: June 2009
Study Completion Date: March 2011
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: CYP3A4*1/*1 Drug: Atorvastatin
The subjects will receive atorvastatin (20 mg single dose) orally with approximately 240 ml of water. Blood samples(4 mL) will be taken prior to dosing and at 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24 and 48 h after drug administration.
Other Names:
  • Lipitor
  • Atorvastatin Calcium Tablets
Active Comparator: CYP3A4*1/*1G Drug: Atorvastatin
The subjects will receive atorvastatin (20 mg single dose) orally with approximately 240 ml of water. Blood samples(4 mL) will be taken prior to dosing and at 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24 and 48 h after drug administration.
Other Names:
  • Lipitor
  • Atorvastatin Calcium Tablets
Active Comparator: CYP3A4*1G/*1G Drug: Atorvastatin
The subjects will receive atorvastatin (20 mg single dose) orally with approximately 240 ml of water. Blood samples(4 mL) will be taken prior to dosing and at 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24 and 48 h after drug administration.
Other Names:
  • Lipitor
  • Atorvastatin Calcium Tablets

Detailed Description:
Large variability exists in the individual response to statins. CYP3A polymorphisms likely contribute to variable response to those drugs primarily metabolized by CYP3A including atorvastatin.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   35 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent.
  • Subjects must be >=35 years and <=70 years of age.
  • Subjects must have an LDL-C concentration >=2.6 mmol/L and TC concentration >=4.14 mmol/L
  • Body mass index (BMI) must be within the range of 19 to 30 for patients.
  • Subjects must have documented coronary heart disease with one or more of the following features:

    • Documented stable angina (with evidence of ischemia on exercise testing)
    • History of myocardial infarction
    • History of percutaneous coronary intervention (with or without stent placement)
    • Documented history of unstable angina or non-Q wave myocardial infarction.

Exclusion Criteria:

  • Diabetes and endocrine or metabolic disease.
  • Congestive heart failure defined by New York Heart Association (NYHA) as Class III or IV.
  • Uncontrolled cardiac arrhythmia.
  • Uncontrolled hypertension (Systolic BP >160 mm Hg and/or Diastolic BP >100 mmHg on two consecutive measurements).
  • Liver or kidney disease confirmed by abnormal lab values or function.
  • Smokers who report cigarette use of more then 10 cigarette per day.
  • Subjects who consume >2 alcoholic drinks a day. (A drink is: a can of beer, glass of wine, or single measure of spirits).
  • Known human immunodeficiency virus (HIV) positive.
  • Cancer.
  • Subjects who are on any of the following concomitant medications:

    • Medications that are potent inhibitors of CYP3A, including cyclosporine, itraconazole, fluconazole, and ketoconazole, erythromycin or clarithromycin, nefazodone, protease inhibitors,mibefradil and large amounts of grapefruit juice (>1 quart/day).
    • Lipid-lowering agent: niacin (>200 mg/day) taken within 5 weeks, fibric acid derivatives taken within 8 weeks.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00973986


Locations
China, Guangdong
Guangzhou General Hospital of Guangzhou Military Command
Guangzhou, Guangdong, China, 510010
Sponsors and Collaborators
Liuhuaqiao Hospital
Guangdong Province, Department of Science and Technology
Investigators
Study Director: Zhao Shujin, PhD Guangzhou General Hospital of Guangzhou Military Command
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Department of pharmacy, Guangzhou General Hospital of Guangzhou Military Command
ClinicalTrials.gov Identifier: NCT00973986     History of Changes
Other Study ID Numbers: YWLCSY-0900328
08110831
GZJQZYY-003
ATR-01
GD080625
20081001
First Submitted: September 4, 2009
First Posted: September 9, 2009
Last Update Posted: November 29, 2011
Last Verified: September 2009

Keywords provided by Liuhuaqiao Hospital:
atorvastatin
genetic polymorphisms
coronary heart disease
pharmacokinetics
CYP3A

Additional relevant MeSH terms:
Heart Diseases
Coronary Disease
Coronary Artery Disease
Myocardial Ischemia
Cardiovascular Diseases
Vascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Atorvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors